High Prevalence of Alterations in DNA Mismatch Repair Genes of Lynch Syndrome in Pediatric Patients with Adrenocortical Tumors Carrying a Germline Mutation on TP53

Carregando...
Imagem de Miniatura
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2020
Título da Revista
ISSN da Revista
Título do Volume
Editora
MDPI
Citação
CANCERS, v.12, n.3, article ID 621, 12p, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Adrenocortical cancer is a rare malignant neoplasm associated with a dismal prognosis. Identification of the molecular pathways involved in adrenal tumorigenesis is essential for a better understanding of the disease mechanism and improvement of its treatment. The aim of this study is to define the prevalence of alterations in DNA mismatch repair (MMR) genes in Lynch syndrome among pediatric patients with adrenocortical neoplasia from southern Brazil, where the prevalence of a specific TP53 germline mutation (p.Arg337His) is quite high. Thirty-six pediatric patients were retrospectively evaluated. Immunohistochemistry (IHC) for theMMR enzymes MLH1, MSH2, MSH6, and PMS2, as well as next-generation sequencing (NGS) were performed. For IHC, 36 pediatric tumors were tested. In all of them, the expression of all evaluated MMR proteins was well-preserved. For NGS, 35 patients with pediatric tumor were tested. Three patients (8.57%) with the TP53 p.Arg337His germline mutation presented pathogenic and likely pathogenic variants in the MMR genes (two in MLH1 and one in MSH6). The prevalence of alteredMMR genes among pediatric patients was elevated (8.57%) and higher than in colorectal and endometrial cancer cohorts. Pediatric patients with adrenocortical tumors should, thus, be strongly considered as at genetic risk for Lynch syndrome.
Palavras-chave
adrenal tumor, DNA mismatch repair, TP53
Referências
  1. Almeida MQ, 2008, J CLIN ENDOCR METAB, V93, P3524, DOI 10.1210/jc.2008-0065
  2. Bilimoria KY, 2008, CANCER, V113, P3130, DOI 10.1002/cncr.23886
  3. Boland CR, 1998, CANCER RES, V58, P5248
  4. BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0
  5. Caron O, 2012, B CANCER, V99, P99, DOI 10.1684/bdc.2011.1522
  6. Chang LS, 2018, APPL IMMUNOHISTO M M, V26, pE15, DOI 10.1097/PAI.0000000000000575
  7. Custodio G, 2012, MOL CELL ENDOCRINOL, V351, P44, DOI 10.1016/j.mce.2011.10.019
  8. Dackiw APB, 2001, WORLD J SURG, V25, P914, DOI 10.1007/s00268-001-0030-7
  9. Dillon JL, 2017, HUM PATHOL, V70, P121, DOI 10.1016/j.humpath.2017.10.022
  10. Dominguez-Valentin M, 2020, GENET MED, V22, P15, DOI 10.1038/s41436-019-0596-9
  11. Else T, 2014, ENDOCR REV, V35, P282, DOI 10.1210/er.2013-1029
  12. Fassnacht M., 2009, ADRENOCORTICAL CARCI, P23
  13. Fassnacht M., 2018, EUR J ENDOCRINOL, V179, pG1
  14. FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3
  15. Fishel R, 2015, J BIOL CHEM, V290, P26395, DOI 10.1074/jbc.R115.660142
  16. Giardiello FM, 2014, GASTROENTEROLOGY, V147, P502, DOI 10.1053/j.gastro.2014.04.001
  17. Heath JA, 2015, FAM CANCER, V14, P545, DOI 10.1007/s10689-015-9810-3
  18. Huang SC, 2014, J PEDIATR GASTR NUTR, V58, P144, DOI 10.1097/MPG.0000000000000179
  19. Jones JS, 2004, CLIN CANCER RES, V10, P5845, DOI 10.1158/1078-0432.CCR-03-0590
  20. Kebebew E, 2006, WORLD J SURG, V30, P872, DOI 10.1007/s00268-005-0329-x
  21. Kopanos C, 2019, BIOINFORMATICS, V35, P1978, DOI 10.1093/bioinformatics/bty897
  22. Kovacs ME, 2009, HUM MUTAT, V30, P197, DOI 10.1002/humu.20942
  23. Kratz CP, 2017, CLIN CANCER RES, V23, pE38, DOI 10.1158/1078-0432.CCR-17-0408
  24. Latronico AC, 2001, J CLIN ENDOCR METAB, V86, P4970, DOI 10.1210/jc.86.10.4970
  25. Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455
  26. LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S
  27. LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747
  28. Li J, 2012, BIOINFORMATICS, V28, P1307, DOI 10.1093/bioinformatics/bts146
  29. Lynch HT, 2015, NAT REV CANCER, V15, P181, DOI 10.1038/nrc3878
  30. LYNCH HT, 1966, ARCH INTERN MED, V117, P206, DOI 10.1001/archinte.117.2.206
  31. Mandelker D, 2015, EXP HEMATOL ONCOL, V4, DOI 10.1186/s40164-015-0026-x
  32. Wielandt AM, 2012, REV MED CHILE, V140, P1132, DOI 10.4067/S0034-98872012000900005
  33. McCarthy AJ, 2019, J PATHOL CLIN RES, V5, P115, DOI 10.1002/cjp2.120
  34. Moreira L, 2012, JAMA-J AM MED ASSOC, V308, P1555, DOI 10.1001/jama.2012.13088
  35. Palomaki GE, 2009, GENET MED, V11, P42, DOI 10.1097/GIM.0b013e31818fa2db
  36. PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251
  37. Pinto Emilia M., 2004, Arq Bras Endocrinol Metab, V48, P647, DOI 10.1590/S0004-27302004000500009
  38. Raymond VM, 2013, J CLIN ONCOL, V31, P3012, DOI 10.1200/JCO.2012.48.0988
  39. Ribeiro RC, 2001, P NATL ACAD SCI USA, V98, P9330, DOI 10.1073/pnas.161479898
  40. Ries L, 2008, SEER CANC STAT REV 1
  41. Sandrini R, 1997, J CLIN ENDOCR METAB, V82, P2027, DOI 10.1210/jc.82.7.2027
  42. Smith TR, 2011, CARCINOGENESIS, V32, P1354, DOI 10.1093/carcin/bgr117
  43. Thompson BA, 2014, NAT GENET, V46, P107, DOI 10.1038/ng.2854
  44. Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034
  45. Vasen HFA, 2005, JAMA-J AM MED ASSOC, V293, P2028, DOI 10.1001/jama.293.16.2028
  46. Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X
  47. VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699
  48. Wajchenberg BL, 2000, CANCER-AM CANCER SOC, V88, P711, DOI 10.1002/(SICI)1097-0142(20000215)88:4<711::AID-CNCR1>3.0.CO;2-W
  49. Young LC, 2007, CARCINOGENESIS, V28, P2131, DOI 10.1093/carcin/bgm153